Bd receives fda 510(k) clearance for updated bd alaris™ infusion system

Bd alaris™ infusion system is the only modular and most comprehensive infusion system on the u.s. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (pca) pumps, respiratory monitoring, auto-identification, dose error reduction software and emr interoperability bd alaris™ infusion system's unique "one system" platform securely connects all patient modules to provide care teams with a single, comprehensive patient view b d sales and service teams will begin actively engaging customers on next steps for their infusion devices; operational capacity investments will enable rapid scale-up of bd alaris ™ infusion system to begin distribution and remediation or replacement of existing devices bd does not expect any material incremental revenue contribution from the bd alaris™ infusion system for the remainder of fy23; expects to absorb initial re-launch investments within fy23 guidance range franklin lakes, n.j. , july 21, 2023  /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced that the updated bd alaris™ infusion system has received 510(k) clearance from the u.s. food and drug administration (fda), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the united states.
BDX Ratings Summary
BDX Quant Ranking